Illumina’s second quarter results reflected strong execution in its core clinical sequencing business, with management highlighting robust demand from U.S. and international clinical customers as the primary growth driver. CEO Jacob Thaysen pointed to growing adoption of the NovaSeq X platform and expanding instrument placements, noting that “strong instrument placements over the past three quarters are expanding customer capacity and will support consumable growth for many quarters to come.” While research and academic markets showed some improvement, management emphasized that the clinical segment remained the engine of performance.
Is now the time to buy ILMN? Find out in our full research report (it’s free for active Edge members).
Illumina (ILMN) Q2 CY2026 Highlights:
- Revenue: $1.16 billion vs analyst estimates of $1.13 billion (9.4% year-on-year growth, 2.5% beat)
- Adjusted EPS: $1.31 vs analyst estimates of $1.23 (6.8% beat)
- Adjusted Operating Income: $260 million vs analyst estimates of $248.1 million (22.4% margin, 4.8% beat)
- The company lifted its revenue guidance for the full year to $4.62 billion at the midpoint from $4.57 billion, a 1.1% increase
- Management raised its full-year Adjusted EPS guidance to $5.35 at the midpoint, a 2.4% increase
- Operating Margin: 21.1%, in line with the same quarter last year
- Organic Revenue rose 6.5% year on year (beat)
- Market Capitalization: $30.18 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Illumina’s Q2 Earnings Call
- Puneet Souda (Leerink Partners) asked about the sustainability of high clinical growth and whether Illumina could exceed its high single-digit 2027 revenue target. CEO Jacob Thaysen reiterated confidence in the clinical market’s momentum and emphasized the durability of current demand trends, while maintaining the existing long-term growth targets.
- Tycho Peterson (JPMorgan) pressed on the risk of over-earning from parallel consumables usage during the transition from legacy platforms to NovaSeq X. Thaysen downplayed the risk, noting that platform transitions are standard and that customers continue to operate older instruments alongside X units without creating artificial demand spikes.
- Vijay Kumar (Evercore ISI) inquired about the step-down in third-quarter guidance and the role of AI-related revenues. Thaysen and CFO Ankur Dhingra attributed the phasing to normal seasonality and highlighted early but growing contributions from BioInsight and the Billion Cell Atlas, with AI still in the early stages of revenue impact.
- Mike Ryskin (BofA Securities) asked about potential inventory effects and the impact of an extra week in the fourth quarter. Dhingra clarified that the extra week would largely benefit consumables revenue by about half a percentage point, and that instrument variability, not inventory, drives quarter-to-quarter fluctuations.
- Kyle Mikson (Canaccord Genuity) sought clarity on tracking multi-omics revenue and future disclosure. Thaysen explained that most multi-omics products are reported within consumables, while BioInsight revenues appear in services, and committed to ongoing updates as these segments scale.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will be watching (1) how quickly consumables revenue accelerates from the expanded NovaSeq X installed base, (2) early adoption and revenue contributions from new multi-omics and spatial biology offerings like StrataMap and SomaScan, and (3) sustained strength in clinical markets, especially in oncology and rare disease applications. Execution on integrating data-driven solutions such as BioInsight and maintaining margin discipline amid cost pressures will also be important to monitor.
Illumina currently trades at $202.35, down from $205.09 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
